8-K from Ligand Pharma Highlights Co. is Eligible to Receive $1.6M Upon Initiation of Retrophin's Phase 3 Trial o f Sparsentan, ~$5.99M Upon Filing of NDA in FSGS, Potential Net Milestones of $65M+ in the Future, 9% Net Royalties